• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nektar Therapeutics

    8/19/25 3:24:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001808356
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NEKTAR THERAPEUTICS
    SEC File Number
    000-24006
    Address of Issuer
    455 MISSION BAY BOULEVARD SOUTH
    SAN FRANCISCO
    CALIFORNIA
    94158
    Phone
    4154825300
    Name of Person for Whose Account the Securities are To Be Sold
    Wilson Mark Andrew
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    67617974.901901857308/19/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common08/15/2025Restricted Stock VestingIssuerCheckbox not checked67608/15/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    08/19/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark Wilson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NKTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    6/24/2025$60.00 → $100.00Buy
    BTIG Research
    6/24/2025$6.50 → $120.00Buy
    H.C. Wainwright
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    11/4/2024$7.00Overweight
    Piper Sandler
    9/30/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on Nektar Therapeutics with a new price target

    BTIG Research reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $100.00 from $60.00 previously

    6/24/25 2:02:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Nektar Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $120.00 from $6.50 previously

    6/24/25 1:36:32 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00

    4/11/25 8:15:16 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

    Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75, EASI-90, and vIGA-AD Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study Top-line Phase 2b data for rezpegaldesleukin in alopecia areata to be reported in December 2025 SAN FRANCISCO, Nov. 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) t

    11/8/25 5:45:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics Reports Third Quarter 2025 Financial Results

    SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable securities on September 30, 2025 were $270.2 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities at September 30, 2025 includes $107.2 million of net proceeds from the secondary offering closed on July 2, 2025 and $34.3 million of net proceeds for the issuance of registered stock under the Company's filed at-the-market, "ATM", offering. Fo

    11/6/25 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

    SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London. Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-

    10/30/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Whitfield Roy A

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:52:37 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Greer R Scott

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:51:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chess Robert

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:51:27 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    SEC Filings

    View All

    Nektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/10/25 6:31:01 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nektar Therapeutics

    10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/6/25 5:58:42 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/6/25 4:24:36 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. 

    10/28/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. T

    7/31/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

    Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA Rapid onset of EASI reduction and magnitude of itch improvement show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator Robust dose-dependent reduction of inflammatory biomarkers in atopic dermatitis including TARC/CCL17, periostin, MDC/CCL22, and IL-19 Safety profile consistent with previously reported results Data expec

    6/24/25 7:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

    BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

    5/11/22 8:01:00 AM ET
    $NKTR
    $TWST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

    SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

    11/15/21 8:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/15/24 4:18:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care